*Comments are invited on:* (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

*Proposed Projects:* Public Health Service Acquisition Regulation—PHSAR Part 380—Special Program Requirements Affecting PHS Acquisitions, and Part 352—Solicitation Provisions and Contract Clauses—0990–0128—Extension—This clearance request addresses recordkeeping and reporting requirements in the Public Health Service Acquisition Regulation (PHSAR) for acquisitions involving safety and health, drugs and medical supplies, reusable cylinders, laboratory animals and the Indian Self-Determination Act. *Respondents:* State or local governments, Businesses or other for-profit, non-profit institutions, Small businesses; *Burden Information for Drugs and Medical Supplies—Total Number of Respondents:* 50; *Annual Frequency of Response:* three times; *Average Burden per Response:* 2 hours; *Estimated Annual Burden for Drugs and Medical Supplies Requirement:* 300 hours—Burden Information for Indian Self-Determination Act—*Total Number of Respondents:* 591; *Annual Frequency of Response:* one time; *Average Burden per Response:* 2 hours; *Estimated Annual Burden for Indian Self-Determination Act Requirement:* 1,182 hours—Burden Information for Reusable Cylinders—*Total Number of Respondents:* 16; *Annual Frequency of Response:* five times; *Average Burden per Response:* 1 hour; *Estimated Annual Burden for Reusable Cylinders Requirement:* 80 hours—Burden Information for Laboratory Animals—*Total Number of Respondents:* 51; *Annual Frequency of Response:* one time; *Average Burden per Response:* 10 hours; *Estimated Annual Burden for Laboratory Animals Requirement:* 510 hours—Burden Information for Safety and Health—*Total Number of Respondents:* 59; *Annual Frequency of Response:* one time; *Average Burden per Response:* 8 hours; *Estimated Annual Burden for Health and Safety Requirement:* 472 hours—Burden Information for Additional Payment Provisions—*Total Number of Respondents:* 454; *Annual Frequency of Response:* three times; *Average Burden per Response:* 1 hour; *Estimated Annual Burden for Additional Payment Requirement:* 1,362 hours—Total Burden: 3,906 hours.

Send comments to Cynthia Agens Bauer, OS Reports Clearance Officer, Room 503H, Humphrey Building, 200 Independence Avenue S.W., Washington, DC 20201. Written comments should be received within 60 days of this notice.

Dated: April 15, 1997.

**Dennis P. Williams,**

*Deputy Assistant Secretary, Budget.*

[FR Doc. 97–10503 Filed 4–22–97; 8:45 am]

**BILLING CODE 4150–04–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee*: Nonprescription Drugs Advisory Committee with Representation from the Endocrinologic and Metabolic Drugs Advisory Committee.

*General Function of the Committee*: The committee reviews and evaluates available data concerning the safety and effectiveness of over-the-counter (nonprescription) human drug products for use in the treatment of a broad spectrum of human symptoms and diseases.

*Date and Time*: The meeting will be held on May 13, 1997, 8:30 a.m. to 5 p.m. An open public hearing portion is scheduled from 8:30 a.m. to 9:30 a.m.

*Location*: Holiday Inn—Bethesda, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

*Contact Person*: Andrea Neal or Angie Whitacre, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12541. Please call the Information Line for up-to-date information on this meeting.

*Agenda*: The committee will hear presentations and discuss data submitted regarding the switch from prescription to over-the-counter status of new drug application (NDA) 16–640/S072, Questran® Powder (cholestyramine resin) and NDA 19–669/S020, Questran® Light (cholestyramine resin with aspartame), Bristol Myers Squibb, for the reduction of elevated serum cholesterol.

*Procedure*: The meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by May 8, 1997. Those desiring to make formal presentations should notify the contact person before May 8, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: April 17, 1997.

**Michael A. Friedman,**

*Deputy Commissioner for Operations.*

[FR Doc. 97–10476 Filed 4–22–97; 8:45 am]

**BILLING CODE 4160–01–F**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of the Committee*: Peripheral and Central Nervous System Drugs Advisory Committee.

*General Function of the Committee*: The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in neurological disease.

*Date and Time*: The meeting will be held on May 8, 1997, 8:30 a.m. to 5 p.m. An open public hearing portion is scheduled from 1 p.m. to 2 p.m.

*Location*: Holiday Inn—Bethesda, Versailles Ballrooms I, II, and III, 8120 Wisconsin Ave., Bethesda, MD.

*Contact Person*: Ermona B. McGoodwin or Danyiel D'Antonio,